» Articles » PMID: 9815945

P53 Antibodies in Patients with Various Types of Cancer: Assay, Identification, and Characterization

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 1995 Dec 1
PMID 9815945
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Alteration of the p53 gene is the most frequent genetic alteration in human cancer and leads to the accumulation of mutant p53 in the nucleus of tumor cells. In addition, it has been shown that patients with various types of neoplasia have p53 antibodies in their sera which could be used as an indirect diagnostic procedure for p53 alteration. Using a new ELISA, we have analyzed the sera from more than 1000 patients with various types of cancer and from healthy blood donors. We demonstrate that p53 antibodies are detected mainly in cancer patients and are strictly proportional to the occurrence of p53 mutations. Using various immunological approaches, these antibodies were unambiguously demonstrated to be directed toward the human p53 protein. Isotyping analysis of these antibodies strongly suggested that they correspond to a humoral response to the p53 protein which accumulates in the tumor cell. This finding suggests that serological analysis, combined with histochemistry, is suitable for assessing the integrity of the p53 gene in cancer patients.

Citing Articles

Redefining serological diagnostics with immunoaffinity proteomics.

Walter J, Eludin Z, Drabovich A Clin Proteomics. 2023; 20(1):42.

PMID: 37821808 PMC: 10568870. DOI: 10.1186/s12014-023-09431-y.


Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer.

Sassu C, Palaia I, Boccia S, Caruso G, Perniola G, Tomao F Int J Mol Sci. 2021; 22(24).

PMID: 34948446 PMC: 8707281. DOI: 10.3390/ijms222413650.


Re-evaluating the clinical significance of serum p53 antibody levels in patients with oral cancer in Japanese clinical practice.

Gohara S, Yoshida R, Kawahara K, Sakata J, Arita H, Nakashima H Mol Clin Oncol. 2021; 15(4):209.

PMID: 34462664 PMC: 8375037. DOI: 10.3892/mco.2021.2372.


Immunotherapy Advances for Epithelial Ovarian Cancer.

Hartnett E, Knight J, Radolec M, Buckanovich R, Edwards R, Vlad A Cancers (Basel). 2020; 12(12).

PMID: 33322601 PMC: 7764119. DOI: 10.3390/cancers12123733.


Mutant p53 as an Antigen in Cancer Immunotherapy.

Sobhani N, DAngelo A, Wang X, Young K, Generali D, Li Y Int J Mol Sci. 2020; 21(11).

PMID: 32521648 PMC: 7312027. DOI: 10.3390/ijms21114087.